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Psoriasis Is Characterized by Accumulation of
Immunostimulatory and Th1/Th17 Cell-Polarizing
Myeloid Dendritic Cells
Lisa C. Zaba1, Judilyn Fuentes-Duculan1, Narat John Eungdamrong1, Maria Veronica Abello1,
Inna Novitskaya1, Katherine C. Pierson1, Juana Gonzalez2, James G. Krueger1 and Michelle A. Lowes1
Myeloid dermal dendritic cells (DCs) accumulate in chronically inflamed tissues such as psoriasis. The
importance of these cells for psoriasis pathogenesis is suggested by comparative T-cell and DC-cell counts,
where DCs outnumber T cells. We have previously identified CD11cþ -blood dendritic cell antigen (BDCA)-1þ
cells as the main resident dermal DC population found in normal skin. We now show that psoriatic lesional skin
has two populations of dermal DCs: (1) CD11cþBDCA-1þ cells, which are phenotypically similar to those
contained in normal skin and (2) CD11cþBDCA-1 cells, which are phenotypically immature and produce
inflammatory cytokines. Although BDCA-1þ DCs are not increased in number in psoriatic lesional skin
compared with normal skin, BDCA-1 DCs are increased 30-fold. For functional studies, we FACS-sorted
psoriatic dermal single-cell suspensions to isolate these two cutaneous DC populations, and cultured them as
stimulators in an allogeneic mixed leukocyte reaction. Both BDCA-1þ and BDCA-1 myeloid dermal DC
populations induced T-cell proliferation, and polarized T cells to become T helper 1 (Th1) and T helper 17 (Th17)
cells. In addition, psoriatic dermal DCs induced a population of activated T cells that simultaneously produced
IL-17 and IFN-g, which was not induced by normal skin dermal DCs. As psoriasis is believed to be a mixed Th17/
Th1 disease, it is possible that induction of these IL-17þ IFN-gþ cells is pathogenic. These cytokines, the T cells
that produce them, and the inducing inflammatory DCs may all be important new therapeutic targets in
psoriasis.
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INTRODUCTION
Psoriasis is a common chronic inflammatory skin disease,
which results in great morbidity for severely affected patients.
In recent years, much progress has been made in under-
standing the pathogenesis and treatment of this disease.
We now appreciate that psoriasis results from complex
interactions between T cells, dendritic cells (DCs), and
keratinocytes (Lowes et al., 2007). Until recently, psoriasis
has been considered a classical type 1 autoimmune disease,
with a strong IFN-g T helper 1 (Th1) signal. However, a new
subset of T cells, T helper 17 (Th17) cells, have now been
described in murine models of autoimmune inflammation
(Weaver et al., 2007), and we have reported the presence of
these cells in psoriasis (Lowes et al., 2008). Th17 cells
produce IL-17 and IL-22, and have other important down-
stream pro-inflammatory effects in skin (Liang et al., 2006;
Zheng et al., 2007). DCs may be very central pathogenic
players in psoriasis, both by activating T cells and by
producing amplifying cytokines and chemokines during
inflammation. In the skin, the main DC populations include
epidermal DCs (Langerhans cells) and dermal DCs (myeloid
DCs and plasmacytoid DCs). We were interested in further
characterizing dermal myeloid DCs in psoriasis, as these cells
may be an important therapeutic target.
Recently, we described that the best marker for identifying
dermal myeloid DCs in normal skin is CD11c (Zaba et al.,
2007b). Also, we have previously reported that there is a large
increase in CD11cþ cells in psoriasis (Abrams et al., 1999;
Gottlieb et al., 2005; Lowes et al., 2005). These CD11cþ cells
include a subset of inflammatory DCs called tumor necrosis
factor (TNF)- and inducible nitric oxide synthase (iNOS)-
producing DCs (Tip-DCs) (Lowes et al., 2005). Tip-DCs were
first described in the spleen during a murine model of Listeria
monocytogenes infection (Serbina et al., 2003; Tam and Wick,
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2004). Pathogenicity of these Tip-DCs in psoriasis is suggested by
the rapid downmodulation of Tip-DC products TNF, iNOS, IL-
20, and IL-23 during effective treatment with TNF-blocking drugs
(Zaba et al., 2007a).
In normal skin, CD11cþ cells are nearly all blood
dendritic cell antigen (BDCA)-1þ (Zaba et al., 2007b).
BDCA-1 is also known as CD1c, and this molecule is part
of the CD1 family of invariant major histocompatibility
complex molecules that are important in presentation of
lipid antigens to T cells (Barral and Brenner, 2007). In this
article, we show that unlike normal skin, most of these
CD11cþ cells in psoriatic plaques are actually BDCA-1.
They are relatively immature DCs, with little dendritic
cell–lysosomal-membrane-associated protein (DC-LAMP)
and DEC-205/CD205 coexpression in psoriatic lesions.
Hence, in situ there were two main types of dermal DCs in
psoriasis lesions: CD11cþBDCA-1þ -resident DCs and
CD11cþBDCA-1 inflammatory DCs. Dermal single-cell
suspensions for phenotype analysis and functional studies
showed that both populations were allo-stimulatory and
were able to polarize allogeneic T cells into IL-17-producing
Th17 cells.
RESULTS
Psoriatic myeloid dermal DCs are CD11cþBDCA-1BDCA-3
To quantify cells in each dermal DC compartment, we per-
formed immunohistochemistry on normal skin and psoriasis
paired lesional/nonlesional samples (n¼ 20) (Figure 1).
Both nonlesional and lesional psoriasis samples had fivefold
fewer BDCA-1þ DCs (Po0.001) (Figure 1a and b). However,
BDCA-1 cell counts did not change significantly in a
group of psoriatic patients treated with etanercept (Figure
1a) (Zaba et al., 2007a). There were twofold more BDCA-3þ
DCs compared with normal skin (Po0.001 and Po0.05,
respectively) (Figure 1a and b). The BDCA-3þ antibody gave
some nonspecific keratinocyte staining, as seen by others
(Narbutt et al., 2006), but it is currently the only available
BDCA-3 antibody. In the dermis, there was a leukocyte
pattern of distribution and a DC morphology with this
antibody, and only dermal cells were counted.
CD11cþBDCA-1BDCA-3 cell numbers were calculated
by subtracting BDCA-1 and BDCA-3 cell counts from CD11c
cell counts. Although lesional and nonlesional psoriasis
sections contained similar numbers of BDCA-1þ and
BDCA-3þ cells, CD11cþBDCA-1BDCA-3 cells were
increased 10-fold in psoriasis plaques compared with
nonlesional skin (Po0.001), and 30-fold compared with
normal skin (Figure 1b) (Po0.001). In addition, we performed
FACS on whole blood from normal (n¼ 6) and psoriasis
(n¼6) subjects and found that BDCA-1þ and BDCA-3þ
myeloid DC subsets (MacDonald et al., 2002) were
decreased in peripheral blood of psoriasis patients compared
with normal volunteers (Figure 1c and d). Negative control
staining (without primary antibody) is shown in Supplemen-
tary Figure 1e.
We next evaluated these populations in situ by two-color
immunofluorescence. In previous studies on normal human
skin, we have characterized two populations of myeloid
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Figure 1. CD11cþ dermal DCs are the major DC population accumulating in psoriasis lesional skin. (a) Representative immunohistochemistry of BDCA-1þ
cells, BDCA-3þ cells, and CD11cþ cells in normal, nonlesional and lesional psoriatic skin. (b) Quantification of myeloid DCs per mm skin stained by
immunohistochemistry of normal skin (red boxes; n¼20), nonlesional skin (light blue boxes; n¼ 20), and matched psoriatic lesional skin (dark blue boxes;
n¼ 20). CD11cþBDCA-1BDCA-3 cell numbers were calculated by subtracting BDCA-1 and BDCA-3 cell counts from CD11c cell counts. Error bars indicate
SEM. (*) Po0.05, (***) Po0.001. Bar¼ 100mm.
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CD11cþ dermal DCs: BDCA-1þ dermal DCs comprise
approximately 90% of all CD11cþ dermal cells, and the
remaining 10% of CD11cþ cells are BDCA-1 (Zaba et al.,
2007b). We found that in psoriasis, there was a reversal of
this ratio of BDCA-1þ cells, as the minority of the CD11cþ
cells coexpressed BDCA-1 (Figure 2a). BDCA-1þ cells
aggregated together in dermal clumps (Figure 2a and b),
compared with CD11cþ cells, which were located mostly
in the upper reticular dermis and dermal papillae. BDCA-3
identifies an additional population of myeloid DCs in the
circulation (MacDonald et al., 2002) and in psoriatic dermis
(Figure 2b). This marker was expressed on CD11cþ cells
scattered throughout the dermis and also on blood vessels
(Figure 2c). Similarly, in normal skin dermis, the few BDCA-
3þ cells that were present were CD11cþ , and the BDCA-1
and BDCA-3 identified discrete populations (n¼4) (Figure
1b). As CD11cþBDCA-1þ cells are the major resident
dermal DC population in normal skin, the remainder of our
study compares resident CD11cþBDCA-1þ DCs in normal
skin with CD11cþBDCA-1þ and CD11cþBDCA-1 DCs in
the psoriatic inflammatory infiltrate.
CD11cþ BDCA-1 myeloid dermal DCs include Tip-DC
population
In psoriasis lesional tissue, the majority of CD11cþ cells
were iNOS producing (Figure 3a), and the cellular
iNOS expression appeared punctate and intracytoplasmic.
Resident CD11cþ BDCA-1þ dermal DCs had o10% iNOS
coexpression (Figure 3b). Similarly, TNF was expressed by
490% of CD11cþ cells (Figure 3c) and o20% of CD11cþ
BDCA-1þ dermal DCs (Figure 3d). In addition, iNOS and TNF
identified occasional nonlesional Tip-DCs (Figure 3e) and
many lesional Tip-DCs (Figure 3f). In conclusion, Tip-DCs
were identified as a subpopulation contained predominantly
within the CD11cþ BDCA-1 myeloid DC population.
CD11cþ BDCA-1 inflammatory DCs show some expression of
macrophage markers compared with BDCA-1þ cells
To further characterize the CD11cþ dermal DCs, we evaluated
coexpression with a series of myeloid cell markers (Figures 4 and
5). Over half of CD11cþ DCs expressed low-level CD14 (Figure
4a). Most CD11cþ cells in the papillary dermis were CD14,
whereas most in the reticular dermis were CD14lo. In contrast,
only occasional BDCA-1þ cells expressed CD14 (Figure 4b).
Dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN)/
CD209, a marker of both immature DCs and macrophages in
normal human skin (Zaba et al., 2007b), partially colocalized
with CD11c (Figure 4c) but did not colocalize with BDCA-1
(Figure 4d). Similarly, CD163, a marker of normal dermal
macrophages (Zaba et al., 2007b), blood monocytes, and blood
DCs (Maniecki et al., 2006), was expressed on some CD11cþ
cells (Figure 4e), but not on CD11cþBDCA-1þ DCs (Figure 4f).
In normal skin, CD11c is not expressed on CD163þ macro-
phages (Zaba et al., 2007b), despite the myeloid origin of
macrophages.
Single antigens specific for mature DCs include
DC-LAMP/CD208 and endocytic receptor DEC-205/CD205
(Figure 5). Nearly all DC-LAMPþ and DEC-205þ cells were
in dermal aggregates, and coexpressed CD11c and BDCA-1.
Although most BDCA-1þ cells coexpressed these two mature
DC markers, there were many CD11cþ cells that did not,
identifying BDCA-1 myeloid dermal DCs as less mature
than BDCA-1þ cells.
Myeloid DCs obtained from psoriatic dermis are
immunostimulatory and activate Th17 and Th1 cells
Single cell suspensions of normal skin (n¼ 3) and psoriasis
lesions (n¼ 3) were obtained by enzymatic splitting of the
epidermis, and then culturing the dermis for 2–3 days to allow
the leukocytes to migrate out of the dermal scaffold.
For functional experiments, we then FACS-sorted this bulk
CD11c BDCA-1
BDCA-1 and CD11c BDCA-1 and BDCA-3 CD11c and BDCA-3
BDCA-3 BDCA-1 CD11a BDCA-3
Figure 2. Most CD11cþ myeloid DCs are BDCA-1 in psoriasis lesional skin. (a) The majority of CD11cþ cells in psoriatic dermis were BDCA-1, whereas a
small subset of CD11cþ cells coexpressed BDCA-1þ . (b) BDCA-1 and BDCA-3 identified separate myeloid DC populations in the dermis. (c) Most BDCA-3þ
cells coexpressed CD11c, and some BDCA-3 staining was observed on blood vessels. In all immunofluorescence figures, single-stained controls are above the
merged image, white line denotes dermoepidermal junction, dermal collagen fibers gave green autofluorescence, and antibodies conjugated with a
fluorochrome often gave background epidermal fluorescence. Bar¼ 100mm.
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dermal single cell suspension, obtaining 10,000–50,000 cells
in each population.
DC phenotype. For surface phenotyping of normal and
psoriatic dermal myeloid DCs by FACS, large cells
were gated on CD11cþHLA-DRþ , a classic definition of a
myeloid DC, and further gated according to BDCA-1
expression (Figure 6a). Phenotypic characterization of
BDCA-1þ cells from normal skin (Figure 6a, box 1)
and psoriasis lesions (Figure 6a, Box 2), as well as psoriatic
BDCA-1 cells (Figure 6a, Box 3) is shown in Figure 6b
and Figure 2.
CD11cþBDCA-1þ -resident dermal DCs from both
normal (Figure 6b, row 1) and psoriasis skin (Figure 6b, row 2)
had similar levels of the lineage marker CD11c, and HLA-DR
major histocompatibility complex-II protein. In contrast,
CD11cþBDCA-1 psoriatic dermal DCs (Figure 6b, row 3)
had 10-fold decreased HLA-DR expression. Expression of
costimulatory molecules CD83 and CD86 was highest on
psoriatic CD11cþBDCA-1þ cells. Expression of the
mature DC markers DEC-205/CD205 and CD208/DC-LAMP
was highest on the psoriatic CD11cþBDCA-1þ cells, with a
gradient of expression on psoriatic CD11cþBDCA-1 cells,
and normal skin resident CD11cþBDCA-1þ cells. CD209/
DC-SIGN showed the highest expression on normal skin
CD11cþBDCA-1þ cells, and was not present on BDCA-1
psoriatic DCs (unlike in situ).
CD40 was low on all three populations (Figure 2).
CD11cþBDCA-1 cells from psoriatic lesions showed
three- to sixfold increased CD14 LPS receptor expression
and were 20% smaller than both CD11cþ BDCA-1þ
iNOS and TNF-α
iNOS
BDCA-1CD11c
CD11c
iNOS and TNF-α
CD11c and TNF-α
CD11c and iNOS BDCA-1 and iNOS
BDCA-1 and TNF-α
TNF-αiNOS TNF-α
TNF-α
iNOS BDCA-1 iNOS
TNF-α
Figure 3. CD11cþBDCA-1 DCs contain the Tip-DC population. (a) Most
CD11cþ dermal DCs in psoriatic lesional skin coexpressed iNOS compared
with (b) BDCA-1þ cells. (c) Most CD11cþ dermal DCs in lesional psoriatic
skin coexpressed TNF compared with (d) BDCA-1þ cells. Approximately,
25% of BDCA-1þ cells coexpressed TNF. (e, f) iNOS and TNF were
coexpressed in the same cell, identifying Tip-DCs in situ. Few Tip-DCs were
observed in (e) psoriatic nonlesional skin compared with (f) lesional skin.
Bar¼100 mm.
CD163 and BDCA-1
DC-SIGN and BDCA-1
CD14 and BDCA-1CD14 and CD11c
DC-SIGN and CD11c
CD163 and CD11c
CD163CD163
DC-SIGN
CD14
DC-SIGN
BDCA-1CD11c
CD11c
CD11c CD14BDCA-1
BDCA-1
Figure 4. CD11cþBDCA-1 inflammatory dermal DCs express CD14 and
DC-SIGN. (a) A subset of CD11cþ cells in the reticular dermis expressed low-
level CD14. (b) Few BDCA-1þ dermal DCs coexpressed CD14, and (c) 80%
of CD11cþ cells were DC-SIGNþ . This was not an exclusive myeloid DC
marker, as some DC-SIGNþ cells were not CD11cþ . (d) BDCA-1þ cells did
not coexpress DC-SIGN. (e) CD163þ macrophages showed some CD11c
coexpression. (f) BDCA-1þ cells did not express CD163. Bar¼ 100mm.
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populations. Blood monocytes expressed similar levels of
CD11c and HLA-DR as CD11cþ BDCA-1 psoriatic dermal
DCs (data not shown), but were 99% CD14hi (Figure S2b, row
3, black line no fill) unlike CD11cþ BDCA-1 psoriatic
dermal DCs, which were CD14mid. CD16 FcgRIIIa expression
was similar in all three populations. Thus, psoriatic CD11cþ
BDCA-1þ dermal DCs are phenotypically mature and closer
to normal resident CD11cþBDCA-1þ dermal DCs, whereas
psoriatic CD11cþBDCA-1 cells share phenotypic features
of both DCs and monocytes.
Allo-MLR
To test the immunostimulatory capacity of psoriatic dermal
DC populations, we FACS-sorted DCs (CD11cþHLA-
DRhiBDCA-1þ or CD11cþHLA-DRhiBDCA-1) and macro-
phages (CD163hi) for coculture as stimulators in an
allogeneic mixed leukocyte reactions (allo-MLR) (Figure 7).
Mature monocyte-derived DCs and T cells alone served as
positive and negative controls, respectively. Figure 7 shows a
representative experiment (n¼3). A total of 73.2% of living
T cells stimulated with mature monocyte-derived DCs at a
stimulator/responder ratio of 1:50 on day 8 post-sorting
had undergone extensive proliferation (Figure 7b). MLRs
without a stimulator population (T cells) alone had 2.5%
background proliferation. CD163hi cells were not more
immunostimulatory than T cells alone (2.3%), whereas both
CD11cþBDCA-1þ -resident DCs and CD11cþBDCA-1
inflammatory DCs were similarly immunostimulatory
(55.3% and 64.5%, respectively). Bulk psoriatic dermal
single cell suspensions stimulate 60% (data not shown).
These results suggest that CD163hi cells in psoriasis are
nonimmunostimulatory macrophages expressing low-level
CD11c (Figure 4e), and that although CD11cþBDCA-1 are
phenotypically less mature than the CD11cþBDCA-1þ cells,
they are comparably immunostimulatory.
Induction of intracellular cytokines in T cells. We recently
demonstrated the presence of Th17 cells from the dermis of
psoriatic plaques (Lowes et al., 2008). We now show that
CD11cþ BDCA-1þ and CD11cþ BDCA-1 psoriatic dermal
DCs induce IL-17 production in allogeneic CD4þ T cells.
Psoriatic dermal e´migre´s (n¼3) were sorted as previously
described into CD11cþ BDCA-1 DCs, CD11cþ BDCA-1þ
DCs, or CD163þ macrophages and mixed with normal
donor T cells at a 1:10 stimulator:responder ratio. Normal
skin dermal e´migre´s (n¼ 2) were sorted into BDCA-1þ and
CD163þ populations. Cells were cultured for 9 days before
analysis of T-cell intracellular cytokines and IL-17 and IFN-g
cytokine production in the supernatant. Figure 8 shows a
representative experiment.
There were few T-cells positive for IL-17 or IFN-g
when the T cells were cultured alone (Figure 8a, left), with
marked increases when cells were stimulated with CD3/28
beads (Figure 8a, right). Culture of the dermal single cell
suspensions alone, without addition of the allogeneic T cells,
gave similar results to T cells alone, indicating the capability
of the syngeneic T cells in the suspension (Figure 8b).
There was marked increase in the intracellular cytokine
staining when the dermal DCs were cultured with allogeneic
T cells (Figure 8c), much more so for the psoriasis lesions.
We particularly noted the increase of the IL-17þ IFN-gþ cells
induced by the psoriatic DCs, from 0.2 to 12.1%. The
psoriatic dermal single-cell suspensions also induced more
IL-17 and IFN-g protein than normal skin (Figure 8d). This
was similar to controls of T cells alone and to T cells
stimulated with CD3/CD28 (data not shown).
The psoriatic BDCA-1þ and BDCA-1 populations
were able to induce similar percentages of these
IL-17þ IFN-gþ cells, although less than the bulk dermal
single cell suspensions (Figure 8e and f, right). This
reduction is likely due to the process of FACS-sorting, as
sorting reduces the ability of the DCs to polarize T cells by an
average of sixfold (analysis of the ability of bulk single-cell
suspensions before and after sorting, data not shown). Also, it
was technically difficult to titrate an exact DC:T cell ratio in
bulk e´migre´s, making it difficult to compare results with pure
sorted cells. The BDCA-1þ DCs from normal skin did not
induce IL-17þ IFN-gþ cells (Figure 8e, left), nor did the
normal or psoriatic skin macrophages (Figure 8g).
In summary, normal skin dermal e´migre´s polarized few
Th17 cells, none of which were IL-17 and IFN-g producing,
whereas psoriatic bulk e´migre´s and dermal DCs (BDCA-1þ and
BDCA-1) polarized Th17 cells producing both IL-17 and
IFN-g. CD163þ macrophages from either normal or psoriatic
skin were not able to polarize T cells to produce IL-17.
DEC-205 and BDCA-1
DC-LAMP and BDCA-1DC-LAMP and CD11c
CD11c BDCA-1
DEC-205 and CD11c
DEC-205 DEC-205CD11c BDCA-1
DC-LAMP DC-LAMP
Figure 5. CD11cþBDCA-1þ cells are phenotypically mature dermal DCs in
psoriasis. DC-LAMP and DEC-205 identified mature DCs, often located in
dermal aggregates. (a) DC-LAMPþ cells were CD11cþ , and (b) BDCA-1þ .
(c) DEC-205þ cells were (c) CD11cþ , and (d) BDCA-1þ . There were many
CD11cþ cells that were not positive for these two markers in the psoriatic
dermis. Bar¼ 100mm.
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DISCUSSION
In psoriasis as well as normal skin, myeloid DCs identified
by BDCA-1 were present, and their numbers remained the
same during a course of etanercept therapy. These resident
BDCA-1þ DCs were often in clumps in the dermis and were
positive for mature markers such as DC-LAMP and DEC-205.
In psoriasis, there was a marked increase in CD11cþ cells
currently best identified as BDCA-1 and we have termed
these BDCA-1 dermal cells as ‘‘inflammatory’’ myeloid
DCs. This group of inflammatory cells may be heterogeneous,
including the Tip-DCs, IL-20-producing DCs (Wang et al.,
2006), and IL-23-producing DCs (Lee et al., 2004; Zaba et al.,
2007a). The success of anti-TNF therapies to reduce all these
cytokines and mediators and reverse the psoriatic phenotype
supports the potential pathogenic role of these DCs (Zaba
et al., 2007a). A similar finding was recently described in
normal and diseased kidney, with a stable number of BDCA-
1þ cells but increased DC-SIGNþ cells during inflammation
(Woltman et al., 2007).
We have interpreted our in situ data to indicate that there
is a distinction between BDCA-1þ and BDCA-1 myeloid
DCs. However, there was little difference in the function of
these two FACS-sorted populations ex vivo, as both
BDCA-1þ and BDCA-1 DCs were immunostimulatory in
the allo-MLR and induced Th1, Th17, and a mixed Th1/Th17
cell type. We interpret these findings as confirmation of their
DC function, and an indication that the CD11cþBDCA-1
cells are not monocytes or macrophages (which cannot
stimulate in these tests). Their ability to perform in these
assays indicates their antigen-presenting potential, rather than
being a true characterization of their role in situ during
inflammation. This lack of difference in their function is
perhaps surprising: we had expected the BDCA-1 popula-
tion to be less stimulatory. The similar function of these two
populations may be due to maturation of the BDCA-1 cells
during migration out of the dermis, demonstrated by
acquisition of DC-LAMP by a proportion of BDCA-1 cells
in the single cell suspensions, with concomitant upregulation
of DC-defining functions. Thus, although there are several
limitations to this system, it is currently the only method
available to study the potential functions of these
cells. Another possibility for the similar capability of the
BDCA-1þ versus the BDCA-1 populations is that the
CD11cþBDCA-1 FACS-sorted cells contain a small number
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Figure 6. Psoriatic inflammatory dermal DCs (CD11cþ BDCA-1) are less mature than resident BDCA-1þ dermal DCs. Flow cytometric analysis of
single-cell suspensions of dermal e´migre´s from normal dermis or psoriatic dermis (n¼3 for each). (a) Large cells gated on CD11cþ HLA-DRhi. In normal dermis,
most myeloid DCs were BDCA-1þ (Box 1). In psoriatic dermis, myeloid DCs were either BDCA-1þ (Box 2) or BDCA-1 (Box 3). Percent of myeloid cells
indicated for each quadrant. (b) Histograms in each row were gated on boxes (1–3) as identified above in Figure 6a. Dark gray histogram represents antigen
expression, light gray represents isotype. Median fluorescence intensity is indicated in the upper right or upper left corner of each histogram. Resident BDCA-1þ
myeloid DCs from normal and psoriatic dermis were phenotypically similar, whereas the additional population of BDCA-1 DCs in psoriasis showed lower
HLA-DR and were smaller cells. Psoriatic BDCA-1þ DCs demonstrated the highest expression of DC-LAMP/CD208, and DEC-205/CD205.
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of immunostimulatory BDCA-3þ cells. However, there are
too few BDCA-3þ cells to separate for functional studies, and
in future sorting strategies, we will exclude these cells.
There are several possible mechanisms to explain an
increase in inflammatory myeloid DCs in psoriasis lesional
skin, including arising from in situ DCs in nonlesional skin,
from circulating DC precursors or monocytes. These cells
may arise from BDCA-1þ -resident myeloid DCs that down-
regulate their BDCA-1 surface expression, or even Langer-
hans cells. This is supported by the xenotransplant psoriasis
model, where human transplanted nonlesional skin from
psoriasis patients is grafted onto immunocompetent mice and
the grafts become psoriatic without further intervention
(Nestle et al., 2005). In this model, resident cells in the
nonlesional skin are sufficient and capable of inducing the
psoriatic phenotype, without any contribution from circulat-
ing cells. However, lesional skin immunocytes may behave
differently in this xenotransplant system and may take on
unconventional roles.
Secondly, these inflammatory myeloid DCs may arise from
peripheral blood DC precursors, including hematopoietic
stem-cell precursors, multipotent progenitor, common mye-
loid precursor, circulating pre-DC (CD11cþ HLA-DRhi,
CD16þ ) or monocytes (Randolph et al., 2002; Serbina
et al., 2003; Tacke and Randolph, 2006; Massberg et al.,
2007; Piccioli et al., 2007). It is possible that any of these
precursor cells are ‘‘pre-inflammatory DCs’’, migrating into
the skin in response to a chemokine gradient or other
stimulus, supported by our observation of a reduction of some
circulating DC subsets in psoriasis blood compared with
normal. The concept that the inflammatory DCs arise from
circulating precursors rather than in situ DCs is also
consistent with other murine models, demonstrating that
during steady state, Langerhans cells and dermal DCs are
able to locally proliferate, but during active inflammation
there is migration of peripheral blood DC precursors into the
skin (Bogunovic et al., 2006; Ledgerwood et al., 2008; Liu
et al., 2007; Massberg et al., 2007).
CD11cþBDCA-1 dermal DCs retain some phenotypic
features of their likely peripheral blood precursors, including
smaller size, low-level expression of CD14, and CD163—
supporting the concept that these cells migrate into the skin
from the blood. CD163hi cells, however, when sorted from
psoriasis dermis are not immunostimulatory, thus they can be
distinguished functionally from the immunostimulatory
CD11cþBDCA-1 DC population. Other phenotypic mar-
kers that have been attributed to both inflammatory DCs and
inflammatory macrophages include CD68 (Wang et al.,
2006), CD32 (Dhodapkar et al., 2007), and DC-SIGN/
CD209 (Granelli-Piperno et al., 2005). The colocalization
of some of these antigens may also be due to plasticity
between these immature DC and macrophage populations
within the tissue during inflammation.
In addition to characterization of psoriatic myeloid dermal
DCs, this article presents evidence for Th17 polarization by
psoriatic DCs. Both psoriatic CD11cþBDCA-1þ -resident
DCs and CD11cþBDCA-1 DCs had the capacity to polarize
Th17 cells, although most polarization was induced by bulk
psoriatic dermal cells not damaged by sorting. Moreover,
bulk psoriatic e´migre´s induced Th17 cells producing both
IL-17 and IFN-g compared with normal skin. As psoriasis is
now thought of as a mixed Th17/Th1 disease with strong IL-
17 and IFN-g signatures (Blauvelt, 2007; Ghoreschi et al.,
2007; Lowes et al., 2007), it is possible that these IL-17/IFN-g-
positive T cells induced by psoriatic DCs are pathogenic.
However, Th17 cell induction could also be due to an allo-
response, so future studies are planned to evaluate auto-
logous effects of these DCs, and also to study other skin
diseases to assess psoriasis-specific effects.
In summary, we have demonstrated a marked increase in
CD11cþBDCA-1 myeloid DCs in psoriasis, and this group
of inflammatory DCs contains Tip-DCs. These cells are
immunostimulatory and capable of Th17 polarization, but
their most essential contribution may be to secrete inflam-
matory products such as iNOS, TNF, IL-20, and IL-23. We
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Figure 7. Both psoriatic CD11cþBDCA-1þ resident DCs and
CD11cþBDCA-1 inflammatory DCs were immunostimulatory in an
allo-MLR. Single-cell suspensions of psoriatic dermal e´migre´s were sorted into
(a, left) CD163hi or (a, right) CD3CD45þHLA-DRhiCD11chiBDCA-1þ
or CD3CD45þHLA-DRhiCD11chiBDCA-1 compared with isotype (red).
(b) Gate contains CD3þ proliferating T cells with left-shifted CFSE as cells
proliferated. Positive control (monocyte-derived mature DCs) on day 8
postsorting at 1:50 stimulator:responder ratio. Background proliferation of
T cells alone (2.5%); CD163hi cells did not stimulate above background.
BDCA-1þ and BDCA-1 cells stimulated T-cell proliferation similarly
(both 455%). Representative graphs from three experiments.
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hypothesize that the resident BDCA-1þ are likely the
myeloid DCs capable of classic antigen presentation to
cutaneous T cells, although their dermal location and
organization into clumps associated with T cells suggests
that this function may occur within the skin environment
(‘‘ectopic lymphoid tissue’’) rather than in an extracutaneous
lymphoid organ such as a lymph node (Lew et al., 2004). In
contrast, although BDCA-1 DCs are certainly capable of
robust antigen presentation in an allo-MLR and have the
ability to polarize T cells (DC-defining characteristics), their
main role may actually be as an inflammatory mediator
production house, amplifying and maintaining psoriatic
inflammation. Further studies need to be performed to
prove this, dependant on new tools to study DCs in situ.
We also need new markers to identify these inflammatory
DCs in a positive manner, rather than as a negative
population. We need to understand how and where these
nonresident CD11cþBDCA-1 DCs are generated, to be able
to specifically shut down their production of pro-inflamma-
tory mediators and bring about rapid resolution of clinical
disease.
MATERIALS AND METHODS
Skin samples
Skin punch biopsies (6 mm diameter) were obtained from normal
volunteers and psoriasis patients under a Rockefeller University
IRB-approved protocol. Informed consent was obtained and
the study was performed in adherence with the Declaration of
Helsinki Principles. Lesional and nonlesional samples used for
immunohistochemistry and immunofluorescence were from patients
enrolled in an etanercept clinical trial as described previously
(Zaba et al., 2007a). Biopsies were frozen in OTC (Sakura, Tokyo,
Japan) and stored at 80 1C until required. Dermal single
cells suspensions from normal human skin were obtained from
waste abdominoplasty skin as described previously (Zaba et al.,
2007b). Dermal single-cell suspensions from psoriasis shave biopsies
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Figure 8. Psoriatic dermal DCs induce IL-17/IFN-c-producing T cells. Allogeneic T-cell responders were mixed with FACS-sorted stimulator populations
described in Figure 6, or with bulk e´migre´s from either normal or psoriatic dermal skin, at 1:10 ratio for 9 days. Intracellular cytokine expression of T cells
(live CD3þCD4þCD8 cells) measured by (a–c, e–g) flow cytometry or (d) protein supernatant. (b, c, e–g) Comparison of T-cell polarization of normal dermal
DCs (left panels) with psoriatic dermal DCs (right panels). (a) Controls: T cells alone (left panel) demonstrated baseline intracellular cytokine expression and
T cellsþ beads (right panel) measured intracellular cytokine expression following CD3/CD28 bead stimulation. (b) Bulk e´migre´s without responder T cells
measured baseline T-cell cytokine production in single-cell suspensions. Other stimulator populations mixed with responder T cells were (c) unsorted bulk
e´migre´s, (e) sorted HLA-DRþCD11cþBDCA-1þ dermal DCs, (f) sorted HLA-DRþCD11cþBDCA-1 dermal DCs, or (g) sorted CD163þ macrophages.
Psoriatic bulk dermal DCs induced a population of IL-17/IFN-g-producing T cells, as did BDCA-1þ and BDCA-1 DCs (although to a lesser degree, possibly due
to sorting). Quadrant percentages are indicated by representative graphs from three experiments. (d) Supernatant of the same cultures was collected for analysis
of cytokine protein expression. Bulk psoriatic dermal e´migre´s mixed with allogeneic T cells induced IL-17 and IFN-g production, whereas normal dermal DCs
did not.
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were obtained following overnight incubation in dispase
(Invitrogen Life Technologies, Carlsbad, CA) 1 mg ml1 at 4 1C, to
separate the epidermis. The dermis was cultured for 36–48 hours at
37 1C in RPMI 1640 (Gibco-BRL Life Technologies, Carlsbad, CA)
supplemented with 10% pooled human serum (Mediatech Inc.
Manassas, VA), 0.1% gentamicin reagent solution (Gibco-BRL Life
Technologies), and 1% 1 M HEPES buffer (Sigma, St Louis, MO)
(Lowes et al., 2005).
Antibodies
All antibodies used for immunohistochemistry, immunofluores-
cence, and FACS are listed in Supplementary Table 1a and b.
Immunohistochemistry
Skin sections were stained as described previously (Zaba et al.,
2007b). Positive cells per mm were counted manually using
computer-assisted image analysis (NIH IMAGE 6.1).
Immunofluorescence
Skin sections were stained as described previously (Zaba et al.,
2007b). Images were acquired using appropriate filters of a Zeiss
Axioplan 2I microscope with Plan Apochromat 20 0.7 numerical
aperture lens and a Hagamatsu orca ER-cooled charge-coupled device
camera, controlled by METAVUE software (Universal Imaging,
Ypsilanti, MI). Images in each figure are presented both as single
color stains (green and red) located above the merged image, so that
one can appreciate the localization of two markers on similar or
different cells. Cells that coexpress the two markers in a similar
location are yellow in color. A white line denotes the dermoepidermal
junction. Dermal collagen fibers gave green autofluorescence, and
antibodies conjugated with a fluorochrome often gave background
epidermal fluorescence.
FACS
Cells from dermal cell suspensions or from whole blood were
stained with the antibodies listed in Table 1b. Briefly, cells were
stained for 20 minutes at 4 1C, whole blood samples were lysed with
FACSlyse (BD Biosciences, San Jose, CA) for 20 minutes, all samples
were washed with FACSwash (PBS 0.1% sodium azide and 2% FBS)
(BD Biosciences), and re-suspended in 1.3% formaldehyde (Fisher
Scientific, Pittsburgh, PA) in FACSwash. For intracellular cytokine
staining assays, cells were incubated in aqua marina live/dead dye
(BD Biosciences) for 30 minutes on ice, washed, fixed with 4%
paraformaldehyde (BD Biosciences) for 20 minutes on ice, blocked
in 1:100 mouse serum (BD Biosciences), permeabilized in FAC-
SPerm (BD Biosciensces), incubated simultaneously with intracel-
lular cytokine and extracellular antibodies, washed, and collected.
All samples were acquired using an LSR-II (BD Biosciences) and
analyzed with FlowJo (Treestar, Ashland, OR). Appropriate isotype
controls were used.
FACS sort and MLR
This was performed as described previously (Zaba et al., 2007b;
n¼ 3). Dermal cells from single cell suspensions of psoriatic lesional
skin were stained with CD3, CD45, CD11c, HLA-DR, BDCA-1,
and CD163 antibodies (Table 1b), and sorted on a FACSAria
(BD Biosciences) using a low-pressure setting. Three populations
were obtained: CD163þmacrophages, CD3CD45þCD11cþHLA-
DRþBDCA-1þDCs (‘‘resident myeloid dermal DCs’’), and
CD3CD45þCD11cþHLA-DRþBDCA-1 DCs (‘‘inflammatory
myeloid dermal DCs’’). Responding T cells were obtained from
a normal volunteer by density centrifugation over Ficoll-Paque
Plus (Amersham Biosciences), followed by T-cell purification
using a T-cell-negative selection kit (Dynal, Carlsbad, CA).
Sorted stimulator populations were cocultured with 10 mm
carboxy fluoroscein succinimidyl ester (CFSE)-labeled T cells at a
1:50 ratio, and T-cell proliferation was analyzed on day 8 post-
sorting. Proliferation assays were harvested, stained with
250 ng ml1 propidium iodide to label dead cells, and CD3-APC
for 15 minutes at room temperature. Propidium iodide-negative cells
were gated and then plotted as CFSE versus CD3þ cells, where
proliferating cells diluted their content of CFSE and move to the left
of the nonproliferating cells. The CFSE-low cells were quantified as a
percentage of live cells in the culture. CFSE-labeled T cells alone
were used as negative control, and coculture with monocyte-derived
mature DCs were used as positive control. The process for making
mature DCs has been described previously (Lee et al., 2002).
T-cell polarization assays
Stimulator DC populations were prepared as above for the MLR
(n¼ 3 for psoriasis dermis; n¼ 2 for normal dermis). Unlabeled
bead-separated (Dynal) T cells were used as responding cells.
Stimulator and responder cells were cultured at a ratio of 1:10. for 9
days. Cells were then resuspended in RPMI media and activated for
4 hours using 25 ng ml1 phorbol myristate acetate and 2 mg ml1
ionomycin, in the presence of 10mg ml1 brefeldin A (all Sigma-
Aldrich St Louis, MO) at 37 1C. Unactivated controls were treated
with brefeldin A only. Ethylenediaminetetraacetic acid (2 mM; Fisher
Scientific) was added for 10 minutes at 37 1C to stop activation.
T-cell intracellular cytokine expression was analyzed using the
following antibodies: CD3, CD4, CD8, IFN-g, IL-17, and aqua live-
dead stain. T cells alone were used as a negative control, and T cells
stimulated with CD3/28 beads (Dynal; 1/2 bead per T cell) were
used as a positive control. Before activation, T-cell polarization
assay plates were centrifuged and the supernatant collected for
measurement of cytokine protein concentration using the human
cytokine 25-plex kit (Invitrogen, Carlsbad, CA) on a luminex CS1000
autoplex analyzer (Luminex corporation). The assay was performed
in duplicate according to the manufacturer’s instruction, and results
were averaged.
Statistical analysis
Two-tailed paired Student’s t-test was used to compare normal versus
psoriasis nonlesional and lesional cell counts for BDCA-1þ , BDCA-3þ ,
and CD11cþBDCA-1-BDCA-3 DC populations. The two-tailed
P-values are designated as Po0.05 (*), Po0.01 (**), and Po0.001 (***).
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Table S1b. Antibodies used for flow cytometry.
Figure S1. Additional characterization of myeloid DCs in skin and blood in
healthy volunteers and psoriasis patients.
Figure S2. Additional FACS analysis of myeloid DC populations from normal
and psoriasis single-cell suspensions.
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